dents and students can derive an ambivalent approach to value. Particularly in academic centers where resources seem limitless, attending physicians often suggest additional tests that expand exhaustive differential diagnoses. This builds on trainees' gnawing fear of missing something to establish thoroughness as an unrestrained virtue. The pressures of individualized quality metrics along with compressed inpatient evaluations to minimize length of stay may further reinforce this mindset and encourage defensive testing. These practices contradict and displace discussions of value.
Timeliness of End-of-Life Discussions for Blood Cancers: A National Survey of Hematologic Oncologists
Existing studies suggest a quality gap with respect to end-oflife (EOL) care for patients with blood cancers, 1 and less timely EOL discussions may be partly to blame. Indeed, patients with blood cancers are more likely to receive chemotherapy and be hospitalized when near death, to die in acute care settings, and are less likely to use hospice services than those with advanced solid tumors. 1 A rigorous understanding of when EOL discussions occur for patients with hematologic cancers is a necessary step toward developing targeted interventions to improve the quality of their EOL care.
Methods | From September 16, 2014, through January 21, 2015, we conducted a postal survey of US hematologists who provide direct care for adult patients with hematologic cancers, whom we identified from the clinical directory of the American Society of Hematology. We developed the survey instrument through a synthesis of preliminary data from a series of focus groups with hematologic oncologists, 2 a review of the relevant literature, previously published survey instruments, [3] [4] [5] and formal cognitive debriefing.
To assess the timing of EOL discussions, we asked, "In your experience, end-of-life care discussions with patients who have hematologic cancers typically occur...," with the response options of "too early," "at the right time," or "too late." 3 In addition, we examined the timing of initial conversations about specific aspects of EOL care by asking, "For patients with life-threatening hematologic cancers, when do you typically conduct the initial discussion specifically addressing resuscitation status?," with the response options of "upon presentation or diagnosis," "during a period of stability," "upon disease progression," "during an acute hospitalization," and "when death is clearly imminent." 3 The same stem and responses were used to ask about initial discussions regarding hospice care and preferred site of death. This study was approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board.
Results | Of the 609 eligible hematologic oncologists, 349 (57.3%) completed the survey. Their median age was 52 years, and 75.4% were men. Overall, 42.9% of the hematologists who completed the survey practiced primarily in tertiary centers and 55.4% practiced in community centers. Of the 345 individuals who answered the question about typical timing of EOL discussions, 55.9% reported that, in their experience, these discussions occur "too late." Respondents in tertiary centers were more likely to report late EOL discussions than were those in community centers (64.9% vs 48.7%, P = .003) ( Table 1) , an association that remained significant in multivariable analysis. As for specific topics of EOL care, 42.5% of the respondents reported conducting their first conversation about resuscitation status at less optimal times; 23.2% and 39.9%, respectively, reported that they typically wait until death is clearly imminent before conducting an initial conversation about hospice care or preferred site of death ( Table 2) . Moreover, hematologic oncologists at tertiary centers were less likely to initiate hospice and resuscitation status discussions at more optimal times than were those at community centers. Discussion | Several factors may contribute to untimely EOL discussions in hematologic oncology. First, unlike most solid malignant neoplasms, which are incurable when they reach an advanced stage (stage IV), many advanced hematologic cancers remain potentially curable. This lack of a clear distinction between the curative and EOL phase of disease for many hematologic cancers may delay the initiation of appropriate EOL discussions. 2 Second, physicians may hesitate to conduct EOL discussions because of fear of affecting patients' emotional coping capacity and hope 6 or because physicians themselves find it difficult to "give up" on patients they might potentially have cured. Although many patients with hematologic cancers are cured, many are not. It is estimated that more than 55 000 Americans will die of leukemia, lymphoma, or multiple myeloma in 2015, many more than the annual deaths from common cancers such as breast cancer. 1 Despite this, surprisingly little attention is given to palliative and end-of-life (EOL) issues in hematologic cancers. Yet the quality gap is clear: these patients are less likely to use hospice services, more likely to die in the hospital, and less likely to see a palliative care specialist. 2 Now, however, after many years of relative silence there is hope on the horizon. Several key studies, including the article by Odejide et al, 3 have recently appeared in the literature, each illuminating unique palliative and EOL issues in hematologic cancers. First, it is increasingly clear that patients with hematologic cancer differ from those with solid tumors. For example, many may not actually want to die at home, despite common assumptions and contrary to knowledge about patients with solid tumors. A population-based survey of more than 300 decedents with hematologic cancer found that more than 28% of those reporting a preference wanted an inhospital death, and that another 5.6% preferred a nursinghome death. 4 With the development of improved models of care for patients with hematologic cancer, it is necessary to consider that they may have different perspectives than patients with solid tumors. Because the treatments for these 2 kinds of cancers are often quite different, it is likely that the experiences of patients who have them are probably also different. We must consider these perspectives as we address endof-life quality gaps. Second, the physicians who treat hematologic cancers differ from those who treat solid tumors. For example, specialists in hematologic cancers think differently about trade-offs in risks and benefits of aggressive cancer care. A survey of 182 oncologists at a tertiary care center found that hematologic oncologists were more likely than solid-tumor oncologists to favor chemotherapy with moderate toxic effects and no survival benefit for patients with poor function and a 1-month life expectancy. 5 Similarly, hematologic oncologists reported less comfort discussing EOL issues and were more likely to report a sense of failure on disease progression than were solidtumor oncologists. Given that hematologic malignancies are often quite different in their responsiveness to chemotherapy and intensity of treatment (stem-cell transplantation, high-dose chemotherapies, etc), it makes sense that oncologists who treat these diseases would also have a different perspective. Evidence also suggests that hematologic oncologists are more likely to view palliative care as only late-stage terminal care or hospice care, whereas solid-tumor specialists more often recognize palliative care as a specialty that provides additional support to those facing a serious illness. 6 To date, however, the unique features of these specialists remain underexplored. In this issue, Odejide et al 3 shed more light on this subject, enriching the understanding of hematologic oncologists' perspectives. In their national survey of hematologic oncologists in the United States, 3 important findings emerged. First, 56% of hematologic oncologists believed that EOL discussions occur too late. Second, respondents at tertiary care centers were even more likely to report late discussions than
